Improved survival after acute graft-versus-host disease diagnosis in the modern era

Hanna J. Khoury; Tao Wang; Michael T. Hemmer; Daniel Couriel; Amin Alousi; Corey Cutler; Mahmoud Aljurf; Minoo Battiwalla; Jean Yves Cahn; Mitchell Cairo; Yi Bin Chen; Robert Peter Gale; Shahrukh Hashmi; Robert J. Hayashi; Madan Jagasia; Mark Juckett; Rammurti T. Kamble; Mohamed Kharfan-Dabaja; Mark Litzow; Navneet Majhail; Alan Miller; Taiga Nishihori; Muna Qayed; Joseph H. Antin; Helene Schoemans; Harry C. Schouten; Gerard Socie; Jan Storek; Leo Verdonck; Ravi Vij; William A. Wood; Lolie Yu; Rodrigo Martino; Matthew Carabasi; Christopher Dandoy; Usama Gergis; Peiman Hematti; Melham Solh; Kareem Jamani; Leslie Lehmann; Bipin Savani; Kirk R. Schultz; Baldeep M. Wirk; Stephen Spellman; Mukta Arora; Joseph Pidala

doi:10.3324/haematol.2016.156356

Improved survival after acute graft-versus-host disease diagnosis in the modern era

Hanna J. Khoury, Tao Wang, Michael T. Hemmer, Daniel Couriel, Amin Alousi, Corey Cutler, Mahmoud Aljurf, Minoo Battiwalla, Jean Yves Cahn, Mitchell Cairo, Yi Bin Chen, Robert Peter Gale, Shahrukh Hashmi, Robert J. Hayashi, Madan Jagasia, Mark Juckett, Rammurti T. Kamble, Mohamed Kharfan-Dabaja, Mark Litzow, Navneet MajhailAlan Miller, Taiga Nishihori, Muna Qayed, Joseph H. Antin, Helene Schoemans, Harry C. Schouten, Gerard Socie, Jan Storek, Leo Verdonck, Ravi Vij, William A. Wood, Lolie Yu, Rodrigo Martino, Matthew Carabasi, Christopher Dandoy, Usama Gergis, Peiman Hematti, Melham Solh, Kareem Jamani, Leslie Lehmann, Bipin Savani, Kirk R. Schultz, Baldeep M. Wirk, Stephen Spellman, Mukta Arora, Joseph Pidala

Hematology

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Acute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (P<0.001). Considering the total study population, univariate analysis demonstrated significant improvements in overall survival and treatment-related mortality over time, and deaths from organ failure and infection declined. On multivariate analysis, significant improvements in overall survival (P=0.003) and treatment-related mortality (P=0.008) were only noted among those originally treated with tacrolimus-based graft-versus-host disease prophylaxis, and these effects were most apparent among those with overall grade II acute graft-versus-host disease. In conclusion, survival has improved over time for tacrolimus-treated transplant recipients with acute graft-versus-host disease.

Original language	English (US)
Pages (from-to)	958-966
Number of pages	9
Journal	Haematologica
Volume	102
Issue number	5
DOIs	https://doi.org/10.3324/haematol.2016.156356
State	Published - Apr 30 2017

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2016.156356

Cite this

Khoury, H. J., Wang, T., Hemmer, M. T., Couriel, D., Alousi, A., Cutler, C., Aljurf, M., Battiwalla, M., Cahn, J. Y., Cairo, M., Chen, Y. B., Gale, R. P., Hashmi, S., Hayashi, R. J., Jagasia, M., Juckett, M., Kamble, R. T., Kharfan-Dabaja, M., Litzow, M., ... Pidala, J. (2017). Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica, 102(5), 958-966. https://doi.org/10.3324/haematol.2016.156356

Khoury, HJ, Wang, T, Hemmer, MT, Couriel, D, Alousi, A, Cutler, C, Aljurf, M, Battiwalla, M, Cahn, JY, Cairo, M, Chen, YB, Gale, RP, Hashmi, S, Hayashi, RJ, Jagasia, M, Juckett, M, Kamble, RT, Kharfan-Dabaja, M, Litzow, M, Majhail, N, Miller, A, Nishihori, T, Qayed, M, Antin, JH, Schoemans, H, Schouten, HC, Socie, G, Storek, J, Verdonck, L, Vij, R, Wood, WA, Yu, L, Martino, R, Carabasi, M, Dandoy, C, Gergis, U, Hematti, P, Solh, M, Jamani, K, Lehmann, L, Savani, B, Schultz, KR, Wirk, BM, Spellman, S, Arora, M & Pidala, J 2017, 'Improved survival after acute graft-versus-host disease diagnosis in the modern era', Haematologica, vol. 102, no. 5, pp. 958-966. https://doi.org/10.3324/haematol.2016.156356

@article{41cf399024bf49daa43ab0c45447d016,

title = "Improved survival after acute graft-versus-host disease diagnosis in the modern era",

abstract = "Acute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (P<0.001). Considering the total study population, univariate analysis demonstrated significant improvements in overall survival and treatment-related mortality over time, and deaths from organ failure and infection declined. On multivariate analysis, significant improvements in overall survival (P=0.003) and treatment-related mortality (P=0.008) were only noted among those originally treated with tacrolimus-based graft-versus-host disease prophylaxis, and these effects were most apparent among those with overall grade II acute graft-versus-host disease. In conclusion, survival has improved over time for tacrolimus-treated transplant recipients with acute graft-versus-host disease.",

author = "Khoury, {Hanna J.} and Tao Wang and Hemmer, {Michael T.} and Daniel Couriel and Amin Alousi and Corey Cutler and Mahmoud Aljurf and Minoo Battiwalla and Cahn, {Jean Yves} and Mitchell Cairo and Chen, {Yi Bin} and Gale, {Robert Peter} and Shahrukh Hashmi and Hayashi, {Robert J.} and Madan Jagasia and Mark Juckett and Kamble, {Rammurti T.} and Mohamed Kharfan-Dabaja and Mark Litzow and Navneet Majhail and Alan Miller and Taiga Nishihori and Muna Qayed and Antin, {Joseph H.} and Helene Schoemans and Schouten, {Harry C.} and Gerard Socie and Jan Storek and Leo Verdonck and Ravi Vij and Wood, {William A.} and Lolie Yu and Rodrigo Martino and Matthew Carabasi and Christopher Dandoy and Usama Gergis and Peiman Hematti and Melham Solh and Kareem Jamani and Leslie Lehmann and Bipin Savani and Schultz, {Kirk R.} and Wirk, {Baldeep M.} and Stephen Spellman and Mukta Arora and Joseph Pidala",

note = "Funding Information: CIBMTR Support List The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from Alexion; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Be the Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; *Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children{\textquoteright}s Foundation; The Leukemia & Lymphoma Society; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Merck & Co, Inc.; Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; Perkin Elmer, Inc.; Pfizer, Inc; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals, Inc.; St. Baldrick{\textquoteright}s Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. Publisher Copyright: {\textcopyright} 2017 Ferrata Storti Foundation.",

year = "2017",

month = apr,

day = "30",

doi = "10.3324/haematol.2016.156356",

language = "English (US)",

volume = "102",

pages = "958--966",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "5",

}

TY - JOUR

T1 - Improved survival after acute graft-versus-host disease diagnosis in the modern era

AU - Khoury, Hanna J.

AU - Wang, Tao

AU - Hemmer, Michael T.

AU - Couriel, Daniel

AU - Alousi, Amin

AU - Cutler, Corey

AU - Aljurf, Mahmoud

AU - Battiwalla, Minoo

AU - Cahn, Jean Yves

AU - Cairo, Mitchell

AU - Chen, Yi Bin

AU - Gale, Robert Peter

AU - Hashmi, Shahrukh

AU - Hayashi, Robert J.

AU - Jagasia, Madan

AU - Juckett, Mark

AU - Kamble, Rammurti T.

AU - Kharfan-Dabaja, Mohamed

AU - Litzow, Mark

AU - Majhail, Navneet

AU - Miller, Alan

AU - Nishihori, Taiga

AU - Qayed, Muna

AU - Antin, Joseph H.

AU - Schoemans, Helene

AU - Schouten, Harry C.

AU - Socie, Gerard

AU - Storek, Jan

AU - Verdonck, Leo

AU - Vij, Ravi

AU - Wood, William A.

AU - Yu, Lolie

AU - Martino, Rodrigo

AU - Carabasi, Matthew

AU - Dandoy, Christopher

AU - Gergis, Usama

AU - Hematti, Peiman

AU - Solh, Melham

AU - Jamani, Kareem

AU - Lehmann, Leslie

AU - Savani, Bipin

AU - Schultz, Kirk R.

AU - Wirk, Baldeep M.

AU - Spellman, Stephen

AU - Arora, Mukta

AU - Pidala, Joseph

N1 - Funding Information: CIBMTR Support List The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from Alexion; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Be the Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; *Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children’s Foundation; The Leukemia & Lymphoma Society; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Merck & Co, Inc.; Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; Perkin Elmer, Inc.; Pfizer, Inc; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. Publisher Copyright: © 2017 Ferrata Storti Foundation.

PY - 2017/4/30

Y1 - 2017/4/30

N2 - Acute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (P<0.001). Considering the total study population, univariate analysis demonstrated significant improvements in overall survival and treatment-related mortality over time, and deaths from organ failure and infection declined. On multivariate analysis, significant improvements in overall survival (P=0.003) and treatment-related mortality (P=0.008) were only noted among those originally treated with tacrolimus-based graft-versus-host disease prophylaxis, and these effects were most apparent among those with overall grade II acute graft-versus-host disease. In conclusion, survival has improved over time for tacrolimus-treated transplant recipients with acute graft-versus-host disease.

AB - Acute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (P<0.001). Considering the total study population, univariate analysis demonstrated significant improvements in overall survival and treatment-related mortality over time, and deaths from organ failure and infection declined. On multivariate analysis, significant improvements in overall survival (P=0.003) and treatment-related mortality (P=0.008) were only noted among those originally treated with tacrolimus-based graft-versus-host disease prophylaxis, and these effects were most apparent among those with overall grade II acute graft-versus-host disease. In conclusion, survival has improved over time for tacrolimus-treated transplant recipients with acute graft-versus-host disease.

UR - http://www.scopus.com/inward/record.url?scp=85018996819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018996819&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.156356

DO - 10.3324/haematol.2016.156356

M3 - Article

C2 - 28302712

AN - SCOPUS:85018996819

VL - 102

SP - 958

EP - 966

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -

Improved survival after acute graft-versus-host disease diagnosis in the modern era

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this